Introduction.
Morphogenesis (1, 2) , tissue repair (3, 4) , angiogenesis (5, 6) , uterine involution, and bone resorption (7) , are characterized by intensified tissue remodeling that begins with degradation of the existing extracellular matrix (ECM). Resident cells of tissues can secrete a specialized group of enzymes, matrix metalloproteases (MMPs) (8) , that can degrade ECM macromolecules such as collagens and proteoglycans (9) . Malignant cells can exploit these same proteases to promote tumor invasion and metastasis (10, 11) . MMPs are secreted in a proenzyme form. The activation of MMPs and interaction with their specific inhibitors, TIMPs, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) determine the fate of these enzymes in the extracellular space. Since we initially demonstrated (24) that the propeptide of interstitial collagenase (MMP-1) is cleaved upon activation, proteolytic processing became a generally accepted pathway for activation of MMPs. In vitro, the processing of the propeptide leads to the removal of a conserved Cys residue triggering the "cysteine switch" activation mechanism (25) and a loss of about 10 kDa in molecular weight. Processing of a propeptide can be initiated by a variety of agents and usually includes an auto-catalytic step. Activation of both the monomer and the dimer of purified Gelatinase B (GelB), (26) are no exception to this rule (27) .
The role of proteolytic processing in the mechanism of MMP activation in vivo remains poorly understood. In most cases, the physiological role of GelB is inferred, based on its correlation with enzyme expression although neither enzyme activation nor the appearance of a proteolytically activated form has been demonstrated (28) (29) (30) (31) (32) . Proteolytically activated species of GelB have not been found in the in vivo model of dermal-epidermal separation triggered by antibodies to the hemidesmosomal protein BP-180 (28, 33) . In this model cleavage of serpin a1-proteinase inhibitor by GelB is a critical event. The data gleaned from the literature demonstrate no evidence of proteolytically activated species of GelB in a number of normal and pathological conditions. For example, an increased level of GelB, exclusively in its proenzyme form, was found in samples of synovial fluid and tissue from patients with inflammatory arthritis (29) . Mice injected with lymphoma cells expressing GelB, developed thymic lymphoma more rapidly than those by guest on http://www.jbc.org/ Downloaded from injected with control lymphoma cells, however, no activated enzyme form was detected (30) .
Expression of GelB has been found conducive to the formation of metastasis by murine prostate tumor cells, but the presence of activated enzyme was not evident (31) . GelB was implicated in the pathogenic mechanism of the autoimmune encephalomyelitis (32) while only the proform of the enzyme was present in cerebrospinal fluid.
Expression of GelB in the placenta is developmentally regulated and it is commonly accepted that this enzyme plays an important role in implantation, placental development and in the invasion of the trophoblast into the uterine epithelium (34) (35) (36) (37) (38) (39) (40) (41) (42) . Again there is no evidence of a proteolytically activated species of GelB in human placental tissue (35, 39, 43) . Is expression of GelB incidental to the processes of tissue metabolism or does a non-proteolytic mechanism of GelB activation exist?
Here we report that the mere binding of the GelB proenzyme to gelatin or type IV collagen substrates, induces its enzymatic activity without cleavage of its propeptide. These results, together with the in situ zymography experiments on tissue sections of human placenta, suggest that GelB activation in vivo may occur via an alternative mechanism.
Experimental procedures.
Enzyme purification and activation.
The proform of GelB enzyme was purified from conditioned medium of transfected p2AHT2a cells as described (27) . Monomer and dimer forms of the enzyme were separated by elution from gelatin-Sepharose (Sigma) affinity column using 0 -10% Me 2 
Immunohistochemistry.
Frozen sections of human term placenta were fixed with 3.5% para-formaldehyde and incubated with monoclonal antibodies to human GelB (clone GE -213, Chemicon International), human Blue and analyzed using either gelatin zymography or western blot as described previously (44) .
Control experiments using 
Inhibition of gelatin bound GelB with TIMP -1.
Wells containing GelB bound to gelatin were pre-incubated with TIMP -1 for 15 min at room temperature in 100 µl of 100mM Tris-HCl pH7.5 buffer containing 100mM NaCl, 10 mM CaCl 2 , 0.005% Brij-35 and 1mg/ml BSA. The fluorogenic peptide substrate was then added to the wells and enzymatic activity was measured as described above. K i for pro and activated forms of GelB
Results.
Gelatinolytic Activity In Term Placenta Is Co-Localized With GelB Having Intact
Propeptide.
GelB is secreted in a proenzyme form and can be activated in vitro by proteolytic processing of the pro-peptide (27, 45, 46, 47) with a corresponding loss of apparent molecular weight. In tissues where GelB is expressed, and presumably is active, the presence of the proteolytically activated form of the enzyme has not been demonstrated (28-32, 35, 39, 43 ) . To address this apparent incongruity we have investigated the gelatinolytic activity in human placenta in situ.
Immunohistochemical staining of tissue sections from term placenta revealed the presence of GelB at the placental villus margin, corresponding with the location of the trophoblast bilayer, with minimal expression in the villus core (Fig. 1, A) . A small quantity of GelA was also found (Fig. 1,   B ). Double immunostaining with antibodies against GelB and type IV collagen showed a complete overlap of the two proteins at the trophoblast basal membrane (Fig. 1, C -E) . In addition, micro capillaries inside the villi devoid of type IV collagen also have a small amount of GelB (Fig.1, E) .
Comparison of immunohistochemical staining of sections of placental villi with an in-situ zymogram assay (Fig. 2) revealed that the gelatinolytic activity and GelB were co-localized.
Inclusion of EDTA in emulsion completely abolished the gelatinolytic activity in this assay.
Preincubation of the tissue sections with TIMP-1 (see materials and methods) inhibited gelatinolytic activity starting with TIMP-1 concentration of 3 nM. This activity was also inhibited (Fig. 2, B) in a dose dependent fashion by preincubation of the sections with monoclonal inhibitory antibodies against GelB (clone GE -213). Inhibition could be observed at an antibody concentration of 5 µg/ml (not shown) while almost complete inhibition was achieved at 60 µg/ml.
Monoclonal inhibitory antibody against Gelatinase A (clone CA -4001) had no noticeable effect on the in situ gelatinolytic activity (Fig. 2, C) . These observations suggest that the gelatinolytic activity in term placenta is due to the presence of GelB. We next examined whether an active form of GelB, as judged by the presence of lower molecular weight enzyme species, could be detected in the placenta tissue. The extracts from excised tissue sections were subjected to zymogram and western blot analysis (Fig. 3) . Both monomer and dimer forms of GelB were found to have the molecular weight corresponding to an unprocessed proenzyme form. These data together with the immunohistochemical staining and in situ zymography results suggest that GelB present in human placenta is enzymatically active despite the fact that its proteolytically activated form cannot be detected.
Substrate Binding Of GelB Proenzyme Is Accompanied By Partial Activation In The
Absence Of The Proteolytic Processing Of The Propeptide.
In view of the results described above we examined whether the interaction of GelB with a physiologically relevant ligand(s) can induce enzyme activation in the absence of proteolytic processing of the propeptide. The results presented in Fig.4 show the effect of gelatin substrate binding on the activity of GelB compared to the enzyme in solution. Average specific activities of pro-and activated GelB either free or gelatin-bound are summarized in Table 1 . No significant changes in specific activity were observed upon binding to gelatin of proteolytically activated GelB.
In contrast binding of GelB proenzyme to gelatin induced an approximate 600 fold increase in specific activity compare to that of the proenzyme in solution. The specific activity of bound proenzyme, however, was about 10 fold lower than that of activated GelB. We next examined whether the increase in activity upon binding of GelB proenzyme to gelatin could be attributed to the appearance of the proteolytically activated enzyme species. To investigate this possibility, SDSextracts of gelatin bound enzyme were subjected to Western-blot analysis (Fig. 5) . The control experiments with 35 S-Met labeled enzyme showed that 95% of the gelatin bound enzyme is recovered using the SDS extraction procedure (not shown). Since the activity of bound proenzyme was 10 fold lower than that of activated GelB, the amount of activated enzyme in the extracts is of the pro-and activated forms of GelB of known ratio showed (Fig. 5) that the amount of the activated enzyme form in the extracts did not exceed 0.25 -0.5 %. This number is at least 20 fold lower than expected if the activity of the bound proenzyme is to be explained by the presence of the proteolytically activated enzyme species. These results suggest that the increase in proteolytic activity of GelB upon binding to gelatin can be attributed to an enzyme with an unprocessed propeptide.
To examine whether this activity is limited to a small fluorogenic peptide substrate we assayed the activity of bound proenzyme against a gelatin substrate. The wells of flash plates were coated with H 3 -labeled gelatin and its release was followed after binding of the enzyme. The specific activity of the bound enzyme (Table 1 ) was calculated based on the amount of released gelatin and the amount of the enzyme bound to a well, determined as described above after extraction. The results of this experiment show that both pro-and activated GelB were active against H 3 -labeled gelatin with specific activities of 27.5 and 242.5 pg of gelatin/min/ng respectively. The ratio of specific activities of bound activated vs GelB proenzyme against H 3 -labeled gelatin is in good agreement with that obtained for the peptide substrate.
To further characterize the gelatin bound GelB we examined the inhibitory activity of TIMP-1 against both pro and activated forms of the enzyme (Fig. 6) . The GelB bound to gelatin coated wells was incubated with TIMP -1 in a concentration range of 0 -30 nM of the inhibitor.
Fitting the inhibition curves to the equation for simple non-cooperative binding gave Ki = 9.3±3.4 nM and 2.2±1.0 nM for activated and proenzyme forms respectively. These results show that enzymatic activity of either enzyme form when bound to gelatin was inhibited by TIMP -1 with similar kinetics.
Although gelatin presents a most effective substrate for the study of gelatinases, GelB can bind a number of extracellular matrix components, including laminin, fibrin and type I and type IV collagens (7, 68 proteolytic activity of the proenzyme to a similar degree while the GelB propeptide remained unprocessed (not shown).
Discussion.
Matrix metalloproteases are secreted as pro-enzymes and can be activated in solution by a variety of agents. Initially we showed (24 , 48, 49) that activation of purified pro-MMP1, induced by either partial proteolysis or treatment with organomercurial compounds, resulted in the removal of the propeptide with a corresponding loss in molecular weight of the active enzyme species. Since then it has been established that activation of all known enzymes of this family is accompanied by the proteolytic processing of a propeptide with removal of the conserved cysteine residue triggering a "cysteine switch" activation mechanism (25) . The more detailed analysis of the pathway of MMP-1 activation using organomercurials (24, 48, 49) showed that the initial activation of the pro- antibodies in combination with immunohistochemistry we have shown that GelB expressed in human placental tissue is co-localized with type IV collagen and is enzymatically active. This occurs despite the fact that its proteolytically processed forms cannot be detected in tissue extracts. We have also shown that the mere binding of GelB to gelatin or Type IV collagen coated surfaces was sufficient to induce proteolytic activity of the enzyme. Activation of the proform of GelB, resulting from its binding to a substrate, is not accompanied by a loss of its N-terminal propeptide indicating that its activation is due to a conformational change. Absence of a detectable amount of N-truncated species in this model also suggests that the enzymatically active proform of GelB that is bound to gelatin is not capable of auto-catalytic cleavage of the propeptide under these conditions.
The specific activity of bound pro-GelB against the peptide substrate is about 600 fold higher than the background specific activity of pro-GelB in solution. However, it is about10 fold lower than that of either free or bound proteolytically activated enzyme. The simplest explanation for the relatively low specific activity of bound pro-GelB is that a conformational change induced by binding results in a lesser accessibility of its active center compared to the enzyme with a processed propeptide. This interpretation, however, is not plausible since the ratio of specific In situ zymography was performed as described in Materials and Methods. The tissue sections were pre-incubated for 30 min (A) with buffer; (B) with 20 µg/ml of inhibitory anibodies against GelB (clone GE -213, Chemicon International); (C) with 60 µg/ml of inhibitory anibodies against GelA (clone CA -4001, Chemicon International). The tissue sections were coated with emulsion and incubated further for 38 hours to develop the gelatinolytic activity. Gelatinolytic activity is associated with trophoblast villi and is co-localized with GelB (see fig.1 ) Proteolytically processed forms of GelB dimer or monomer can not be detected in placenta tissue extracts by both zymography and Western-blot analysis. Enzymatic activity of pro -and stromelysin activated GelB in solution (A) or bound to gelatin coated surface (B) was measured as described in Materials and Methods using fluorogenic peptide as a substrate. The amounts of GelB bound to gelatin was determined using quantitative zymography of extracted enzyme as described in Materials and Methods. A: 1,2 -activated dimer, 4 and 2ng, respectively; 3 -activated monomer 2ng; 4 -proform of dimer 2800 ng; 5 -proform of monomer 3000 ng. B: 1 -activated dimer 2.1 ng; 2, 5 -proforme of dimer 17.1 and 10.2 ng,respectively; 3 -activated monomer 2.3 ng; 4 -proform of monomer 12.7 ng. Specific activities calculated from these data are summarized in Table 1 . by guest on 
